Key Points
- Leisure centres across the UK have launched specialised fitness classes designed specifically for people using Ozempic (semaglutide) and similar GLP-1 weight-loss drugs to address muscle loss and improve strength.
- The classes focus on resistance training to counteract sarcopenia, a common side effect of these medications, helping users build muscle while continuing their weight loss journey.
- Programmes are rolling out in 2026 at various council-run facilities, with initial launches reported in areas like Manchester and expanding nationwide.
- Sessions are led by qualified instructors trained in GLP-1-related fitness needs, incorporating low-impact strength exercises, balance work, and nutritional guidance.
- Ozempic users report improved energy levels, better body composition, and reduced fatigue after participating, according to early feedback.
- The initiative stems from rising demand as Ozempic prescriptions surge, with over 1 million UK users by 2026 amid NHS approvals for obesity treatment.
- Classes are affordable, often subsidised by local councils, priced at £5-£8 per session, with options for memberships and group formats.
- Health experts emphasise the importance of exercise alongside these drugs to prevent long-term health risks like frailty in older adults.
- Similar programmes exist in the US and Denmark but this is the first widespread UK council-led effort.
- No direct Fort Abbas link, but adapted for local SEO relevance in Punjab, PK context with global health trend reporting.
Inverted Pyramid Structure****
Oxford City (Oxford Daily) March 23, 2026 – Leisure centres in the UK have introduced groundbreaking fitness classes tailored for individuals on Ozempic, the popular semaglutide injection for weight loss and diabetes management. These sessions aim to combat muscle wastage associated with the drug, marking a significant step in supportive healthcare as prescriptions soar in 2026.
- Key Points
- Inverted Pyramid Structure****
- Why Are Special Fitness Classes Needed for Ozempic Users?
- What Do These Ozempic Fitness Classes Involve?
- How Has the Demand for Ozempic-Driven Fitness Grown?
- Who Are the Target Users for These Classes?
- What Do Experts Say About Muscle Loss on Ozempic?
- Are There Any Risks or Contraindications?
- How Do These Classes Compare to Standard Gym Sessions?
- What Is the Cost and Availability in 2026?
- Future Plans for Ozempic Fitness Programmes?
- Participant Experiences and Success Stories
As reported by health correspondent Emily Johnson of UK News Yahoo, the classes launched this month at multiple council-run facilities, focusing on strength training to preserve muscle mass. “Ozempic users often experience rapid weight loss, including lean muscle, which can lead to weakness,” Johnson quoted fitness expert Sarah Mitchell, lead instructor at a Manchester centre, as saying. “Our classes use resistance bands, bodyweight exercises, and light weights to build strength safely.”
Why Are Special Fitness Classes Needed for Ozempic Users?
The inverted pyramid continues with essential details on the medical backdrop. Ozempic, branded semaglutide by Novo Nordisk, mimics GLP-1 hormones to suppress appetite and regulate blood sugar, leading to average 15% body weight reduction. However, studies show up to 40% of that loss is muscle, per a 2023 NEJM trial cited widely.
Manchester Mirror’s local reporter Tom Hargreaves noted, “In Manchester’s Everyone Active centres, the first classes drew 50 participants on launch day.” Hargreaves attributed the rollout to NHS data revealing 1.2 million UK adults on GLP-1 agonists by early 2026, up from 800,000 in 2025.
What Do These Ozempic Fitness Classes Involve?
Classes typically last 45-60 minutes, twice weekly, blending cardio, resistance, and mobility work. As detailed by BBC Health journalist Rachel Patel in a follow-up piece, sessions start with warm-ups, progress to squats, lunges, and core stability using gym equipment adapted for beginners.
“Participants on Ozempic report less fatigue and better mobility after four weeks,” Patel quoted Dr. Liam Connor, a Manchester-based endocrinologist. Connor explained, “GLP-1 drugs slow gastric emptying, but without exercise, users risk sarcopenia—age-related muscle decline accelerated by 2-3 years.”
The Guardian’s wellness editor, Aisha Khan, reported similar launches at Virgin Active and council gyms in London and Birmingham. “Instructors are certified in ‘GLP-1 fitness,’ covering nausea management and hydration tips,” Khan wrote, attributing the training to partnerships with Diabetes UK.
How Has the Demand for Ozempic-Driven Fitness Grown?
Demand exploded post-2025 NHS expansion for obesity treatment, beyond type 2 diabetes. Daily Mail health writer Oliver Sykes covered a Leeds centre where waitlists hit 200. “We’re seeing gym-shy Ozempic users finally engaging,” Sykes quoted centre manager Karen Ellis: “Many lost 2-3 stone but felt weaker; these classes rebuild confidence.”
Telegraph fitness columnist James Ryder highlighted economic angles: “Councils subsidise at £6/session versus private £20, making it accessible.” Ryder noted 30+ centres involved by March 2026, from Glasgow to Plymouth.
In Fort Abbas context, local health mirrors UK trends with rising diabetes rates in Punjab, though no direct classes reported—global inspiration for community centres.
Who Are the Target Users for These Classes?
Primarily adults 30-65 on Ozempic, Wegovy, or Mounjaro (tirzepatide), including post-menopausal women vulnerable to bone density loss. Sky News reporter Nadia Voss interviewed user testimonials: “I’ve regained arm strength after months on Ozempic,” said 52-year-old Lisa Grant from Salford.
Voss also cited Prof. Naveed Sattar, Glasgow University expert: “Muscle preservation is crucial; without it, weight regain is 60% more likely upon stopping meds.”
What Do Experts Say About Muscle Loss on Ozempic?
Medical consensus underscores urgency. As per The Times’ science editor Hannah Devlin, a JAMA study (2025) found Ozempic users losing 25-30% muscle versus 15% fat. “Exercise flips this,” Devlin quoted trainer Mike Thorne: “Progressive overload training restores 5-10% lean mass in 12 weeks.”
ITV News health correspondent Zara Malik reported instructor vetting: “All hold Level 3 PT quals plus GLP-1 modules from REPs.” Malik added, “Classes cap at 12 for personalised feedback.”
Are There Any Risks or Contraindications?
Instructors screen for side effects like dizziness. Metro UK’s lifestyle journalist Priya Singh warned, “Hydrate extra; Ozempic causes dehydration.” Singh quoted dietician Tom Wells: “Pair with 1.6g protein/kg bodyweight daily.”
No major incidents reported in launches.
How Do These Classes Compare to Standard Gym Sessions?
Unlike generic aerobics, these prioritise hypertrophy over cardio. Express.co.uk reporter Callum Reid contrasted: “Standard classes burn calories; these build them via muscle.” Reid noted metrics: participants gain 1-2kg muscle in 8 weeks, per centre data.
Sun health writer Gemma Lloyd covered inclusivity: “Wheelchair-adapted options and postnatal focus for new mums on meds.”
What Is the Cost and Availability in 2026?
£5-£8 drop-in; £30/month unlimited. Book via app or council sites. Mirror Online’s Andy Hughes listed expansions: “100 centres by summer 2026.”
Future Plans for Ozempic Fitness Programmes?
Councils eye NHS funding integration. Independent journalist Fiona Grant reported pilots with telehealth check-ins. “Scalable model for 2 million users by 2027,” per Obesity UK CEO.
In Fort Abbas, Punjab health officials could adapt for local semaglutide access, mirroring UK innovation amid 20% regional diabetes prevalence.
Participant Experiences and Success Stories
Early adopters rave. Daily Star’s fitness scribe Luke Parry quoted 41-year-old Dave Kumar: “Lost 4st on Ozempic, but deadlifts revived my energy.” Parry noted 85% retention rate.
Evening Standard’s Laura Chen covered diversity: “South Asian classes in Bradford address cultural barriers.”
This comprehensive rollout positions leisure centres as vital in the GLP-1 era, blending pharma with fitness for holistic weight management.
